Literature DB >> 8625527

Elevation of plasma-soluble tumour necrosis factor receptors (TNF-R) in sarcoidosis.

T Nakayama1, S Hashimoto, E Amemiya, T Horie.   

Abstract

Two types of receptor for tumour necrosis factor-alpha (TNF-R), the 55-kD receptor (TNF-RI) and the 75-kD receptor (TNF-RII), have been identified. Soluble TNF-RI (sTNF-RI) and soluble TNF-RII (sTNF-RII) can be measured in culture supernatants and biological fluids, and the role of sTNF-R has been suggested. In the present study, we measured plasma sTNF-RI and sTNF-RII levels in 19 patients with active sarcoidosis by ELISA in order to assess the state of both types of receptors in this disease. Both plasma sTNF-RI and sTNF-RII levels in patients with active sarcoidosis were significantly higher than those in normal control subjects. A longitudinal evaluation of plasma sTNF-RI and sTNF-RII levels showed that the magnitude of changes in sTNF-RII was closely related with the clinical course of sarcoidosis. These results suggest that plasma sTNF-RII levels may be useful parameters for monitoring the clinical course of sarcoidosis as well as markers for identifying disease activity.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8625527      PMCID: PMC2200429          DOI: 10.1046/j.1365-2249.1996.13702.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  3 in total

1.  Inter-relationship between tumour necrosis factor-alpha (TNF-alpha) and TNF soluble receptors in pulmonary sarcoidosis.

Authors:  L Armstrong; N M Foley; A B Millar
Journal:  Thorax       Date:  1999-06       Impact factor: 9.139

2.  Increased interleukin-13 expression in patients with sarcoidosis.

Authors:  H-P Hauber; D Gholami; A Meyer; A Pforte
Journal:  Thorax       Date:  2003-06       Impact factor: 9.139

3.  Quantile-Specific Heritability of Inflammatory and Oxidative Stress Biomarkers Linked to Cardiovascular Disease.

Authors:  Paul T Williams
Journal:  J Inflamm Res       Date:  2022-01-05
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.